HD-OPM Archive
Topics › Aging & longevity

Single dose of donor stem cells raised walking endurance about 20% in frail older adults

Gokhan Can · Feb 25, 2026 · ♥ 18 reactions · 9 comments · original Facebook post
Aging & longevity
AI summary & key facts

Describes a trial of donor bone-marrow mesenchymal stem cells in 148 walking adults aged 70-85 with frailty (118 on varying doses, 30 on placebo). The cells lack immune-triggering surface proteins so no immunosuppressants were needed; at nine months the highest dose group walked about 60 m farther in a six-minute walk test than at baseline.

In a recent study targeting age-related frailty, researchers tested a novel therapy using a single dose of mesenchymal stem cells derived from donated bone marrow. The trial included 148 walking adults aged 70 to 85, with 118 receiving varying doses of the laboratory-grown stem cells and 30 receiving a placebo. Because these specific stem cells lack the surface proteins that typically trigger immune rejection, participants did not need to take risky immunosuppressive medications. The results showed that nine months after the treatment, participants who received the highest dose of stem cells experienced about a 20% improvement in physical endurance, walking an average of 60 meters farther during a six-minute walk test compared to their pre-treatment baseline.

Paper · Nature · 2026Stem cells provide a potent treatment for frailtynature.com

Research cited

#stemcells#walking#frailty#bones#protein
← newer: Shingles vaccine tied to slower biological aging and less inolder: Veritasium documentary on the history and ongoing danger of →